Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Skin Diseases, Papulosquamous 1Skin Diseases 1Psoriasis 1Plaque, Amyloid 1Lymphoma, Follicular 1Bronchiolitis Obliterans Syndrome 1Adenoma, Liver Cell 1

Interventions

ibrutinib 3ruxolitinib 2asciminib 2Alemtuzumab 2sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1ofatumumab 1nilotinib 1montelukast 1mocetinostat 1lonafarnib 1ixekizumab 1fludarabine 1bosutinib 1belumosudil 1baricitinib 1axatilimab 1Voriconazole 1Tomography, X-Ray Computed 1Sofosbuvir 1Saline Solution 1SLC25A33 protein, human 1Rituximab 1Ribavirin 1Respiratory Function Tests 1Prednisone 1Pentostatin 1Oxycodone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bronchiolitis Obliterans Syndrome × baricitinib × Clear all
NCT01490632 2019-09-27

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Eli Lilly and Company

Phase 2 Completed
271 enrolled 32 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous, Plaque, Amyloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡